Novartis und Compugen wollen Proteindatenbank entwickeln - 500 Beiträge pro Seite | Diskussion im Forum

[Nachrichten [wO]]

Der Schweizer Pharmakonzern Novartis hat eine Zusammenarbeit mit dem israelischen Medizinaltechnikunternehmen Compugen bekannt gegeben. Novartis und Compugen planen die gemeinsame Erstellung einer Datenbank für menschliche Proteine. Novartis will die Proteindatenbank nutzen, um Ziele für neue Medikamente zu identifizieren.

Autor: Gerrit Nawracala (© wallstreet:online AG),16:20 02.08.2001

[p2001]

Compugen Names Co-Founder Eli Mintz Chairman Of U.S. Subsidiary


Princeton, NJ - November 14, 2001

Compugen (NASDAQ:CGEN) announced today that Eli Mintz, a co-founder of the Company, has been named chairman of Compugen Inc., the Company`s wholly owned U.S. subsidiary, and senior advisor to Compugen. It is expected that Mr. Mintz will devote approximately forty percent of his time to his new positions. In addition, Mr. Mintz will continue to serve as a member of the parent company`s board of directors.

Since co-founding the Company in 1993, Mr. Mintz has held a number of senior management positions, including chief executive officer of Compugen Ltd. and president of its U.S. subsidiary, which was his most recent position prior to this new appointment. In addition, he has been a key spokesperson for the Company with both scientific and financial audiences.

Martin Gerstel, chairman of Compugen Ltd., said, "As a co-founder of Compugen almost a decade ago, and a member of our most senior management team continuously since that time, Eli has been an important participant and driver of Compugen`s growth and development. We greatly appreciate his past contributions and will miss his full-time involvement. We look forward to the continuing benefit of Eli`s wisdom and involvement in his new positions with the Company."

"I am very proud of Compugen`s development and its role today as a leading participant in the world of life science. When we founded the Company in 1993, our initial plans were to develop special purpose computers to help biologists deal with the enormous amounts of raw data which were then becoming available for the first time. Building on that success, we have now established a broadly based life science company with a unique multi-disciplinary R&D team of more than 100 persons which continues to make important breakthroughs in genomics and proteomics. I am pleased that in my new position I will be able to continue to participate in the further development of the Company while, at the same time, having the time and opportunity to explore some other interests of mine as well as new ventures," said Mr. Mintz.

Prior to co-founding Compugen, Mr. Mintz was marketing director of Orckit Communications and brought to Compugen eight years of experience in the Israeli Defense Forces` Talpiot Program. Mr. Mintz holds a Bachelor of Science degree in physics, mathematics and computer science from The Hebrew University, Jerusalem and an MBA from INSEAD, France.

About Compugen
Compugen (Nasdaq: CGEN) develops and markets platforms, tools and products that accelerate post-genomic research, the advanced study of proteins and protein pathways, and drug target discovery. Compugen`s in-house molecular biology laboratories conduct original genomic and proteomic research and also provide validation for Compugen`s methodologies. Products commercialized to date include: LEADS, Gencarta, DNA Chip design, Z3, ProtoCall, LabOnWeb.com and Bioccelerators. For additional information, please visit Compugen`s Corporate Web Site at www.cgen.com and the Company`s Internet research engine for molecular biologists, www.LabOnWeb.com.